/Investor DB

ALS Investment Fund — Full Portfolio

11 tracked investments · listed companies and verified rows first

Amylyxamylyx.comin𝕏NASDAQ: AMLX

Amylyx is a biopharmaceutical company developing novel therapies for diseases with high unmet medical needs.

BiotechHealthtechCambridge, US

Justin Klee(Director)inJoshua Cohen(Founder)in

BoardStephen D. Chubb(Director)George M. Milne, PH.D.(Director)

Co-investorsAlpha Wave GlobalAvoro Capital AdvisorsBain Capital Life Sciences

Bloom Sciencebloomscience.comin𝕏Series A · Dec 2021 · $12M

Bloom Science is a clinical-stage biotech company developing live biotherapeutic products that replicate the effects of the ketogenic diet through the gut-brain axis.

BiotechDeep TechDigital HealthSan Diego, US

Co-investorsJoyance PartnersPsyMed VenturesSocial StartsApollo Health VenturesLeaps by Bayer

Emulate Bioemulatebio.comin𝕏

Emulate builds Organ-on-a-Chip systems, including platforms, consumables, and pre-assembled BioKits with validated human cell models, to support drug discovery research.

BiotechDeep TechHealthtech

Donald Ingber(Scientific Founder, Board Member, Scientific Advisory Board Chairman)inDaniel Levner(Co-Founder & CTO)inJim Corbett(CEO, Board Member)inLorna Ewart(Chief Scientific Officer)in

Co-investors+ND CapitalNorthpond VenturesAlumni VenturesAlwyn CapitalFourth RealmStray Dog Capital+3 more

Kempharmkempharm.com
Prileniaprilenia.com
ProJenXprojenx.comin𝕏

ProJenX is a clinical-stage biotechnology company developing novel, brain-penetrant therapies for neurodegenerative diseases, with an initial focus on amyotrophic lateral sclerosis (ALS).

BiotechDeep TechMedical DevicesNissequogue, US

Valerie Estess(Director)

BoardJohn Prufeta(Director)inEric Heil(Director)inJoni Mancini(Executive Officer)inBrent R. Stockwell(Chair of the Department of Biological Science, Professor at Columbia University)Hynek Wichterle(Jerry and Emily Spiegel Professor at Columbia University)

Co-investorsMedical Excellence Capital

Quralisquralis.comin𝕏Mar 2023

QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.

BiotechDeep TechMedical DevicesCambridge, US

Kevin Eggan(Co-founder)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Director, Executive Officer, Promoter)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in

Co-investorsDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission BiocapitalMitsui Global Investment+8 more

Uniqureuniqure.comin𝕏

uniQure is a biotech company developing gene therapies for serious genetic diseases.

BiotechHealthtechMedical Devices

Matthew Kapustain

Co-investorsAdvent Life SciencesForesite CapitalHEALTHCARE ROYALTY PARTNERSRidgeback Capital

Verge Genomicsvergegenomics.comin𝕏Series A

Verge Labs builds AI models trained on multimodal human patient data to predict drug targets and patient populations for clinical development, primarily in neuroscience and central nervous system (CNS) disease.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Francisco, US

Alice Zhang(Co-founder & CEO)inJason Chen(Cofounder)inEmily Ripka(Head of Product & Engineering)in

Co-investorsAgent CapitalBOLD LongevityDraper AssociatesFitz Gate VenturesGreat Oaks Venture CapitalKarlin Ventures+28 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Apic BioVectory

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.